Want to see SE:ONCO full AI Analyst Report?
ONCO Stock Chart & Stats
kr4.88
>-kr0.01(-0.39%)
At close: 4:00 PM EST
kr4.88
>-kr0.01(-0.39%)
Day’s Range― - ―
52-Week Rangekr1.26 - kr6.19
Previous CloseN/A
Volume80.98K
Average Volume (3M)2.28M
Market Cap
kr631.42M
Enterprise Valuekr305.43
Total Cash (Recent Filing)kr205.15M
Total Debt (Recent Filing)kr130.80M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding387,851,200
10 Day Avg. Volume1,913,694
30 Day Avg. Volume2,284,999
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)kr149.95M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained TTM revenue growth of +17% indicates commercial traction and increasing market adoption of the company’s offerings. Over 2–6 months this durable top-line expansion supports scale, absorbs fixed R&D/commercial costs, and reduces per-unit cash burn, improving runway and strategic optionality.
Exceptionally High Gross MarginA gross margin near 97% reflects a high-margin biotech product profile typical of targeted therapies. This structural margin advantage can sustainably support future profitability if R&D and SG&A growth are controlled, enabling faster conversion of incremental revenue into operating leverage.
Focused Oncology Franchise (Multiple Myeloma)A clear strategic focus on targeted therapies in multiple myeloma aligns with durable structural demand for specialty oncology drugs. Niche expertise and product focus support differentiated clinical development, regulatory clarity and premium pricing opportunities over the medium term.
Bears Say
Severe Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow (~-200m TTM) creates ongoing financing dependence. Over the next several months this raises liquidity and dilution risk, constrains discretionary investment, and forces management to prioritize near-term funding over long-term strategic options.
Elevated Leverage For A Loss-Making BusinessMeaningful debt (131–142m) and ~1.7x debt-to-equity amplify refinancing and interest risks for a company still reporting large losses. High leverage limits financial flexibility, increases cost of capital, and raises vulnerability to market disruptions during crucial commercialization or approval milestones.
Large Operating And Net LossesVery large negative EBIT and net margins show the cost base far outstrips current revenues. Although margins have improved versus prior years, the company remains distant from break-even, making profitability contingent on sustained revenue growth and disciplined cost control over multiple quarters.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.19 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr631.42M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Aug 27, 2026 which is in 35 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on May 13, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 387,851,200 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 38.715%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Xspray Pharma AB
―
Active Biotech AB
―
Cantargia AB
―